Sign in

    Cooper Companies Inc (COO)

    Q1 2024 Earnings Summary

    Reported on Jan 10, 2025 (After Market Close)
    Pre-Earnings Price$93.60Last close (Feb 29, 2024)
    Post-Earnings Price$102.04Open (Mar 1, 2024)
    Price Change
    $8.44(+9.02%)

    What went well

    • Cooper Companies expects accelerated revenue growth in its CooperVision division, with the CEO expressing confidence in returning to double-digit growth as early as Q2, supported by improved capacity to meet strong demand for their contact lenses.
    • The company has raised its full-year guidance for both revenues and earnings, increasing CooperVision's organic revenue growth guidance to 8%-9% and non-GAAP EPS guidance to $3.50-$3.58, reflecting strong business momentum.
    • The myopia management market presents a significant growth opportunity for Cooper Companies, with products like MiSight and SightGlass expected to drive future revenues in a market estimated to be worth billions of dollars.

    What went wrong

    • The company's PARAGARD product is experiencing underlying demand struggles and faces potential competition from a generic product that could impact sales if approved.
    • The SightGlass joint venture is generating losses reported below operating income, which continues to be a drag on earnings.
    • The consolidation of revenue reporting for CooperVision products, such as MiSight being reported under "sphere," may reduce transparency in product performance reporting.

    Q&A Summary

    1. Guidance Increase for CooperVision
      Q: What gives confidence to raise CooperVision growth guidance?
      A: We achieved 7% growth in Q1, almost reaching 8%, and with improved capacity and strong February performance, we're confident in returning to double-digit growth starting in Q2. Thus, we're raising our guidance from 7%-9% to 8%-9%.

    2. Margin Outlook and FX Impact
      Q: How will gross and operating margins look for fiscal 2024?
      A: Gross margins are expected to be similar to last year, depending on product mix. Operating margins should increase year-over-year. However, FX will have a more negative impact in Q2 and Q3, affecting margins.

    3. PARAGARD Competitive Risks
      Q: Is there concern about PARAGARD competition and growth slowing?
      A: While underlying demand is a struggle, we anticipate PARAGARD to be roughly flat year-over-year. Potential generic competition hasn't materialized yet, so we're cautiously optimistic and have adjusted guidance from 4%-6% to 5%-7% growth for CooperSurgical.

    4. Contact Lens Market Growth
      Q: Do you still expect 5%-7% contact lens market growth?
      A: Yes, we maintain the expectation of 5%-7% market growth but lean toward the upper end due to strong fundamentals and ongoing transition to daily lenses.

    5. Capacity Constraints and Demand
      Q: How are capacity constraints affecting ability to meet demand?
      A: Demand remains strong, and while we can't meet all of it yet, our improved capacity allows us to support existing customers and launch new products. Additional capacity coming online positions us for strong years ahead.

    6. Price Increases and Consumer Acceptance
      Q: How are price increases impacting growth and are consumers accepting?
      A: We're seeing low single-digit price increases, around 2%-3%, mostly through product mix shifts to higher-priced dailies. There's no significant pushback from consumers, and future price increases depend on the economy.

    7. Myopia Management Market Potential
      Q: What's the opportunity with MiSight and SightGlass in myopia management?
      A: The myopia management market is large, potentially in the billions of dollars. Spectacles with SightGlass will become first-line therapy, especially for children, and MiSight contact lenses will serve those needing added convenience or better compliance. Together, they offer significant growth potential.

    8. Fertility Market Growth Continuation
      Q: Can fertility growth continue at double digits?
      A: Yes, despite headlines, the global fertility market remains strong, and underlying characteristics support continued double-digit growth for years.

    9. Regional Performance Variances
      Q: Why was AsiaPac growth lower compared to Europe in CVI?
      A: AsiaPac was impacted by capacity constraints, particularly in Japan, affecting product allocation. Europe performed strongly due to effective teams and product availability improvements.

    10. New Product Innovations
      Q: What are the plans for new product launches in silicone hydrogel lenses?
      A: We continue to expand our MyDay family with recent launches like MyDay Multifocal and MyDay Energys. There's still work to bring these products to more markets, and future launch activity will focus on expanding existing products.

    Related Publications